340B drug pricing allows eligible healthcare organizations to purchase certain outpatient drugs at discounted prices. When a covered entity uses contract pharmacies, however, it also takes on important responsibilities for registration, oversight, recordkeeping, and compliance.
Understanding these requirements is essential for organizations that want to use contract pharmacy arrangements without creating avoidable 340B compliance problems.
What Is a 340B Contract Pharmacy?
A 340B contract pharmacy is a pharmacy that works with a 340B covered entity to provide pharmacy services to the entity’s eligible patients. The pharmacy can dispense 340B drugs on behalf of the covered entity under a written agreement.
Contract pharmacies are not required for every covered entity. Organizations can choose how to provide pharmacy services based on their operational needs and applicable federal and state requirements.
When an organization does use a contract pharmacy, the arrangement must be properly established and registered. The pharmacy must be listed as active in the 340B Office of Pharmacy Affairs Information System (OPAIS) before it can dispense 340B drugs on the covered entity’s behalf.
What Are the Main Contract Pharmacy Requirements?
A covered entity remains responsible for ensuring that its contract pharmacy arrangements comply with 340B program requirements.
Several areas deserve particular attention.
Written agreements
The covered entity should have a fully executed written agreement with each contract pharmacy. The agreement should identify the relevant pharmacy locations and establish how the arrangement will operate.
HRSA recommends that covered entities have legal counsel review contracts and related documents for compliance with applicable requirements.
OPAIS registration
The contract pharmacy must be correctly registered in OPAIS before dispensing 340B drugs.
The pharmacy’s name and address should match the information in the agreement and the OPAIS record. Covered entities should also keep their OPAIS information current and notify HRSA when relevant arrangements change.
Patient eligibility
340B drugs can only be used for eligible patients under the applicable program requirements. Contract pharmacy processes should therefore have controls that support accurate patient eligibility determinations.
A weak eligibility process can create serious compliance concerns, particularly when large numbers of transactions are processed across multiple locations.
Preventing duplicate discounts
Covered entities also need controls to prevent duplicate discounts. A 340B drug should not also generate a Medicaid rebate when doing so would create a prohibited duplicate discount.
Medicaid billing arrangements require particular attention. HRSA states that 340B drugs generally may not be used for Medicaid fee-for-service patients at a contract pharmacy unless an arrangement is established to prevent duplicate discounts and reported to HRSA.
Why Contract Pharmacy Oversight Matters
One of the biggest misunderstandings about contract pharmacy 340B arrangements is that responsibility ends once the contract is signed.
It does not.
The covered entity remains responsible for ensuring that its contract pharmacy arrangements meet 340B requirements. HRSA specifically expects covered entities to maintain oversight and auditable records.
This means organizations should have a process for reviewing contract pharmacy activity rather than relying entirely on the pharmacy or a third-party administrator.
Regular oversight can help identify problems before they become larger compliance issues.
How Should Organizations Monitor Contract Pharmacies?
A strong 340B program management process should combine routine monitoring with formal audits.
HRSA recommends quarterly internal audits and annual independent audits of utilized contract pharmacies, or more frequently when appropriate. It also recommends written policies and procedures describing contract pharmacy oversight.
Organizations should consider reviewing:
- Patient eligibility determinations
- Dispensing records
- Purchasing records
- Billing information
- Medicaid billing arrangements
- Contract pharmacy registration
- OPAIS information
- Inventory and transaction records
- Policies and procedures
- Exception reports
Reconciliation is particularly useful. Comparing dispensing, purchasing, and billing records can help identify potential diversion or duplicate discounts.
What Restrictions Should Covered Entities Watch?
Contract pharmacy compliance is not limited to one rule. Several areas can affect how a 340B arrangement operates.
Incorrect or outdated OPAIS information
An organization should not assume its registration remains accurate forever. Pharmacy ownership, locations, contacts, and other information can change.
HRSA advises covered entities to keep OPAIS records accurate and up to date. Incorrectly listed contract pharmacies can create compliance problems and may result in removal from the program.
Diversion
340B drugs must not be diverted to individuals who are not eligible under the program.
Covered entities should therefore have controls that identify who qualifies for 340B drugs and make sure those controls work consistently across contract pharmacy locations.
Duplicate discounts
Duplicate discounts remain another major area of risk. Organizations need processes that help prevent the same drug from receiving both a 340B discount and an impermissible Medicaid rebate.
Inadequate records
A 340B covered entity needs records that demonstrate compliance. HRSA audits can include contract pharmacy arrangements and review transaction records, internal controls, policies, eligibility, OPAIS information, diversion controls, and duplicate discount controls.
Poor documentation can make it difficult to demonstrate that a process is working even when the underlying activity appears correct.
How Can Organizations Improve 340B Audit Readiness?
Audit readiness should be part of regular 340B program management rather than something an organization starts after receiving an audit notice.
A practical approach includes four steps.
First, document the process.
Maintain current policies that explain how contract pharmacies are selected, registered, monitored, and audited.
Second, review the data.
Regularly reconcile relevant purchasing, dispensing, and billing information. Look for unusual transactions, gaps, and exceptions.
Third, check the contracts and registrations.
Make sure agreements are current and pharmacy information is accurately reflected in OPAIS.
Fourth, address issues quickly.
When a potential compliance problem is identified, document the investigation and corrective action. HRSA provides a self-disclosure process for covered entities that identify certain violations such as diversion or duplicate discounts.
Organizations looking to strengthen these processes can also evaluate specialized 340B compliance and program management services as part of their broader compliance strategy.
What Should Organizations Do When a Pharmacy Arrangement Changes?
Changes to a contract pharmacy relationship should be handled carefully.
For example, a pharmacy may change ownership, move locations, change its operating name, or terminate an agreement. Organizations should review the agreement, update applicable records, and make sure the pharmacy’s OPAIS information remains accurate.
HRSA specifically advises covered entities to notify the agency promptly when contract pharmacy arrangements change and to verify that pharmacy details match their agreements and OPAIS records.
A simple change-management process can prevent outdated records from becoming a larger compliance issue later.
Common Questions About 340B Contract Pharmacies
Are 340B covered entities required to use contract pharmacies?
No. Covered entities can choose how to provide pharmacy services. Options may include contract pharmacies, in-house pharmacy services, or administering drugs directly to patients, subject to applicable requirements.
Can a contract pharmacy dispense 340B drugs before registration?
No. The contract pharmacy must be properly registered and listed as active in 340B OPAIS before dispensing 340B drugs on behalf of the covered entity.
Who is responsible for contract pharmacy compliance?
The covered entity remains responsible for ensuring that its contract pharmacy arrangements comply with 340B requirements. This includes appropriate oversight and maintaining auditable records.
How often should contract pharmacies be audited?
HRSA recommends quarterly internal audits and annual independent audits, with more frequent reviews when necessary. Organizations should consider their own risk profile and operational complexity when designing their monitoring program.
Conclusion
340B drug pricing can provide meaningful value to eligible healthcare organizations, but contract pharmacy arrangements require active oversight. Registration, patient eligibility, OPAIS accuracy, Medicaid billing, diversion controls, duplicate discount prevention, and audit-ready records all need attention.
The strongest 340B programs treat contract pharmacy compliance as an ongoing operational responsibility, not a one-time setup task. Regular monitoring, clear policies, reliable records, and timely corrective action can help covered entities maintain stronger control over their 340B program while reducing avoidable compliance risk.
Mots Clés : 340B program